Verastem, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Verastem, Inc. (VSTM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -2.88% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-04
- Verastem, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -2.88%, a 754.55% decline from fiscal 2023.
- Verastem, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.44%.
- Verastem, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.08%.
- Verastem, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.44%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -2.88% 10-K · filed 2026-03-04 |
| 2023-12-31 | 0.44% 10-K · filed 2025-03-20 |
| 2022-12-31 | -0.08% 10-K · filed 2024-03-14 |
| 2021-12-31 | -0.44% 10-K · filed 2023-03-14 |
| 2020-12-31 | -0.60% 10-K · filed 2022-03-28 |
| 2019-12-31 | -1.41% 10-K · filed 2021-03-18 |
| 2018-12-31 | -0.65% 10-K · filed 2020-03-11 |
| 2017-12-31 | -1.24% 10-K · filed 2019-03-12 |
| 2016-12-31 | -3.88% 10-K · filed 2018-03-13 |
| 2015-12-31 | -3.02% 10-K · filed 2017-03-23 |
| 2014-12-31 | -6.25% 10-K · filed 2016-03-03 |
| 2013-12-31 | -4.76% 10-K · filed 2015-03-10 |
| 2012-12-31 | -5.96% 10-K · filed 2014-03-06 |
| 2011-12-31 | -4.78% 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |